Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 5,900 shares, a decline of 50.0% from the December 15th total of 11,800 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 51,000 shares, the days-to-cover ratio is presently 0.1 days.
Several large investors have recently bought and sold shares of OPNT. Marquette Asset Management LLC bought a new position in shares of Opiant Pharmaceuticals during the 3rd quarter worth about $59,000. Morgan Stanley increased its holdings in shares of Opiant Pharmaceuticals by 39.1% during the 3rd quarter. Morgan Stanley now owns 10,714 shares of the technology company’s stock worth $80,000 after purchasing an additional 3,012 shares during the period. Squarepoint Ops LLC bought a new position in shares of Opiant Pharmaceuticals during the 3rd quarter worth about $90,000. GSA Capital Partners LLP increased its holdings in shares of Opiant Pharmaceuticals by 100.4% during the 3rd quarter. GSA Capital Partners LLP now owns 27,110 shares of the technology company’s stock worth $203,000 after purchasing an additional 13,583 shares during the period. Finally, BlackRock Inc. increased its holdings in shares of Opiant Pharmaceuticals by 43.6% during the 3rd quarter. BlackRock Inc. now owns 29,491 shares of the technology company’s stock worth $220,000 after purchasing an additional 8,948 shares during the period. Institutional investors own 19.32% of the company’s stock.
Separately, ValuEngine upgraded shares of Opiant Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, December 11th.
Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its earnings results on Thursday, November 12th. The technology company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.34. The firm had revenue of $9.11 million for the quarter, compared to the consensus estimate of $7.94 million. Opiant Pharmaceuticals had a net margin of 25.32% and a negative return on equity of 2.43%. As a group, equities research analysts forecast that Opiant Pharmaceuticals will post -0.83 EPS for the current year.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
Recommended Story: Beta
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.